Chicago, IL – June 2, 2026 – The American Society of Clinical Oncology (ASCO) 2026 annual meeting, held from May 29th to June 2nd, once again served as a critical platform for unveiling cutting-edge research in oncology. Among the many significant presentations, two studies focused on metastatic colorectal cancer (mCRC) generated considerable expert interest, offering potential advancements for patients with specific genetic mutations, namely BRAF and RAS. While both studies presented encouraging data, the rapidly evolving treatment paradigms, particularly in BRAF-mutated mCRC, cast a complex light on their potential future impact.
This year’s ASCO meeting highlighted two key areas of mCRC research: the exploration of novel combinations for RAS-mutated disease and the assessment of new agents for BRAF V600E-mutated mCRC. GlobalData Healthcare analysts provided in-depth insights into these studies, examining their methodologies, results, and the broader implications for patient populations and the pharmaceutical industry.
Cardiff Oncology’s Onvansertib: A Potential Breakthrough for RAS-Mutated mCRC
One of the most closely watched presentations involved Cardiff Oncology’s Phase II randomized CRDF-004 trial, investigating the efficacy of onvansertib, an oral small molecule polo-like-kinase 1 (PLK1) inhibitor, when added to standard of care (SoC) chemotherapy in patients with RAS-mutated unresectable mCRC. This study directly addresses a significant unmet need, as RAS mutations, encompassing KRAS and NRAS, are prevalent in approximately 45% of mCRC patients and are associated with resistance to conventional anti-epidermal growth factor receptor (EGFR) therapies.
The CRDF-004 Trial Design and Objectives
The CRDF-004 trial (NCT06106308) enrolled 110 patients who were receiving first-line SoC chemotherapy. This backbone comprised either FOLFIRI (leucovorin, fluorouracil, and irinotecan) or FOLFOX (leucovorin, fluorouracil, and oxaliplatin), in combination with bevacizumab. The innovative aspect of the trial was the addition of onvansertib, administered at two dose levels (20mg and 30mg), to this established regimen and then compared against SoC alone. The primary endpoint of the study was the objective response rate (ORR), a measure of how many patients experienced a significant reduction in tumor size. Key secondary endpoints included progression-free survival (PFS), duration of response (DoR), and a comprehensive assessment of safety.
Promising Efficacy Data with FOLFIRI Combination
Early data from the CRDF-004 trial suggested a positive trend towards meeting its primary endpoints. Notably, the combination of onvansertib with FOLFIRI and bevacizumab demonstrated promising antitumor activity and an acceptable safety profile. In contrast, the addition of onvansertib to the FOLFOX backbone did not appear to confer a significant benefit in this specific patient group.
Within the trial, patients were randomized across six arms: bevacizumab plus FOLFIRI or bevacizumab plus FOLFOX, each with or without onvansertib at either 20mg or 30mg. Baseline characteristics were generally well-balanced across all treatment arms, ensuring a fair comparison. The onvansertib 30mg dose, when combined with FOLFIRI and bevacizumab, achieved an impressive confirmed ORR of 72.2%. This starkly contrasts with the ORR of 42.1% observed in the control arm, which received FOLFIRI plus bevacizumab alone. The FOLFOX plus bevacizumab control arm showed an ORR of 44.4%.
Furthermore, the PFS data was particularly compelling. When comparing the onvansertib arms (both 20mg and 30mg) combined with FOLFIRI and bevacizumab against the SoC (FOLFIRI plus bevacizumab), the median PFS was not reached in the experimental arms. This is in significant contrast to the control arm, where median PFS was 10.97 months, as assessed by the investigator. The hazard ratio (HR) for PFS in favor of the onvansertib combination was 0.53, indicating a substantial reduction in the risk of disease progression.
Safety Profile and Future Directions
The safety profile of onvansertib was reported as manageable, with neutropenia being the most frequently observed Grade 3 or higher adverse event. While these initial results are highly encouraging, it is important to acknowledge that the per-arm sample sizes remain relatively small, necessitating further confirmatory evidence. Cardiff Oncology has already taken a proactive step by announcing plans for a Phase III evaluation of onvansertib at the 30mg dose in combination with FOLFIRI and bevacizumab, underscoring their confidence in these findings.
Addressing a Critical Unmet Need in RAS-Mutated mCRC
The treatment of RAS-mutant mCRC represents one of the most significant challenges in the field. The prevalence of KRAS and NRAS mutations in nearly half of mCRC patients, and their known association with resistance to anti-EGFR therapies, highlights the urgent need for novel therapeutic strategies. Current first- and second-line SoC, which typically involves bevacizumab plus chemotherapy, has remained largely unchanged for two decades, with median PFS ranging from nine to eleven months, underscoring the limitations of existing treatments.
Onvansertib stands out as a distinctive development-stage asset due to its mutation-agnostic approach. This characteristic positions it as a potentially viable option across the entire spectrum of RAS-mutant disease, irrespective of the specific mutation subtype. The drug’s potential extends beyond CRC, with ongoing clinical investigations in various other malignancies, including pancreatic cancer, chronic myelomonocytic leukemia, breast cancer, small-cell lung cancer, and skin cancer. GlobalData’s analyst consensus forecast projects onvansertib to achieve over $1 billion in sales by 2032, reflecting the considerable commercial expectations tied to its broad therapeutic potential.
Shanghai Kechow Pharma’s Kolupin Combo: Navigating a Crowded BRAF-Mutated Landscape
The second notable presentation focused on Shanghai Kechow Pharma’s Phase III randomized, open-label trial (NCT06008119) evaluating Kolupin (tunlametinib), a novel oral mitogen-activated extracellular signal-regulated kinase (MEK1/2) inhibitor, in combination with vemurafenib (a BRAF inhibitor) for patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC) who had received at least one prior line of systemic therapy.
Trial Design and Primary Endpoint Achievement
This trial aimed to improve outcomes for a specific subset of mCRC patients characterized by the BRAF V600E mutation. Patients in the experimental arm received the combination of Kolupin and vemurafenib, while the control arm received physician’s choice of therapy. The primary endpoint of this study was PFS. Key secondary endpoints included overall survival (OS), ORR, disease control rate (DCR), and safety.
The combination of tunlametinib and vemurafenib demonstrated a statistically significant improvement in PFS compared to the control arm. The median PFS in the experimental arm was 4.2 months, a marked improvement over the 1.5 months observed in the control arm. This translated to a favorable HR of 0.342, indicating a substantial reduction in the risk of disease progression for patients receiving the Kolupin combination.
Efficacy and Safety Observations
Beyond PFS, the Kolupin combination also showed encouraging results in other efficacy measures. The confirmed ORR was 26.7% in the experimental arm, significantly higher than the 3.7% observed in the control arm. Similarly, the DCR was 85.7% for the Kolupin combination versus 40.4% for the control. However, OS data remained immature at the time of presentation, meaning it would require further follow-up to draw definitive conclusions.
A critical point of consideration for this trial was the baseline characteristics of the patient population. There was an imbalance between the arms, with approximately 61.9% of patients in the experimental arm having three or more metastatic sites, compared to 46.2% in the control arm. Such imbalances can potentially influence treatment outcomes and need to be carefully considered when interpreting the results.
The Evolving Treatment Paradigm for BRAF V600E-Mutated mCRC
The presentation of the Kolupin trial results at ASCO 2026 occurs within a rapidly evolving landscape for BRAF V600E-mutated mCRC. The tunlametinib plus vemurafenib trial was initiated prior to the landmark BREAKWATER trial results becoming available. The BREAKWATER trial (NCT04607421) has since established a new frontline standard of care. Pfizer’s Braftovi (encorafenib) in combination with cetuximab and chemotherapy received US Food and Drug Administration (FDA) approval, demonstrating a doubling of OS in BRAF V600E-mutant mCRC patients, with a median PFS of 12.8 months and a median OS of 30.3 months. These results represent one of the most significant breakthroughs in CRC treatment in recent years.
In the previously treated setting, the BEACON CRC trial had previously set a benchmark with the combination of Braftovi and cetuximab, yielding a median PFS of 4.2 months and a median OS of 8.4 months. This context raises the pertinent question of whether replacing vemurafenib with encorafenib in the Kolupin combination could lead to meaningfully improved outcomes.
Challenges and Future Prospects for Kolupin
The VIC regimen (vemurafenib, irinotecan, and cetuximab/panitumumab) was an earlier BRAF V600E-targeted combination to receive a recommendation from the US National Comprehensive Cancer Network (NCCN). However, it was subsequently removed from the guidelines in favor of newer BRAF-targeted regimens that offered more mature efficacy data and a better tolerability profile.
The BREAKWATER trial has significantly narrowed the pool of BRAF inhibitor-naïve patients available for later-line treatments, which was the specific population studied in the Kolupin trial. Furthermore, the post-encorafenib retreatment space appears to be consolidating around encorafenib-cetuximab rechallenge strategies rather than alternative BRAF inhibitor combinations. This trend further limits the potential niche for the tunlametinib plus vemurafenib combination.
Global Applicability and Regulatory Hurdles
The extent to which these findings will translate to a global setting remains uncertain. A notable observation from the trial was that over 50% of enrolled patients had left-sided tumors, despite BRAF V600E-mutant colorectal cancer being predominantly right-sided. The presenter attributed this to geographic differences within the Chinese population. Given that the trial was conducted exclusively in China, differences in tumor biology might limit its applicability to Western patients. Regulatory agencies such as the FDA and the European Medicines Agency (EMA) may require additional bridging studies before granting approval, further complicating the path forward for Kolupin in these markets.
Conclusion: A Dynamic Future for mCRC Treatment
The presentations at ASCO 2026 underscore the rapid advancements and the increasing complexity of mCRC treatment. Cardiff Oncology’s onvansertib shows significant promise for the large and underserved population of RAS-mutated mCRC patients, offering a potentially mutation-agnostic approach. The data presented is robust enough to warrant further investigation in a Phase III setting.
Conversely, while Shanghai Kechow Pharma’s Kolupin trial demonstrated a statistically significant improvement in PFS, the evolving treatment landscape for BRAF V600E-mutant mCRC, particularly with the advent of the BREAKWATER regimen, presents substantial challenges for its future clinical utility and market penetration. The success of emerging therapies will increasingly depend not only on their efficacy but also on their ability to integrate seamlessly into established and rapidly advancing treatment algorithms, and to demonstrate clear advantages in well-defined patient populations. ASCO 2026 has clearly illustrated that while progress is being made, the journey towards optimal mCRC management is a continuous and dynamic process.
About the Author
